Comparable stake leader
Third Rock Ventures V, L.P.
SEC ownership of Rapport Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0002012593.
Disclosed value leader
Third Rock Ventures V, L.P.
Comparable rows
6/50
Latest evidence
30 Oct 2026
- Public ticker
- RAPP on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Third Rock Ventures V, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Third Rock Ventures V, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0002012593
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Rapport Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Third Rock Ventures V, L.P.
Disclosed value leader
Third Rock Ventures V, L.P.
Comparable rows
6/50
Latest evidence
30 Oct 2026
3/4/5
13D/G
13F
Lead comparable stake: 13%
44 rows are not safely comparable across share classes.
13D/G row: Third Rock Ventures V, L.P.
Showing 1-8 of 50 holder rows.
Quick read
Third Rock Ventures V, L.P. leads the comparable SEC ownership view at 13%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Third Rock Ventures V, L.P.'s linked filing trail.
Comparable ownership
Top 5
Third Rock Ventures V, L.P.
13%
Capital International Investors
6.1%
Cormorant Asset Management, LP
5.6%
BlackRock, Inc.
5%
JOHNSON & JOHNSON
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. |
3/4/5
13D/G
Director, 10%+ Owner
|
13%
Reported 13D/G
· 30 Jun 2026
|
$291,591,350
8,678,314 shares
|
-$34,391,226 | 30 Oct 2026 |
| Capital International Investors |
13D/G
13F
Company
|
6.1%
Reported 13D/G
· 30 Jun 2026
|
$121,757,990
2,921,958 shares
|
$0 | 30 Jun 2026 |
| Cormorant Asset Management, LP |
13D/G
|
5.6%
Reported 13D/G
· 30 Jun 2026
|
$110,738,900
2,657,521 shares
|
-$12,501,000 | 30 Jun 2026 |
| BlackRock, Inc. |
13D/G
|
5%
Reported 13D/G
· 31 Dec 2025
|
$72,741,637
2,397,549 shares
|
$0 | 31 Dec 2025 |
| JOHNSON & JOHNSON |
13F
13D/G
Company
|
4.9%
Reported 13D/G
· 30 Sep 2025
|
$59,959,771
1,784,517 shares
|
— | 30 Sep 2026 |
| Sofinnova Venture Partners XI, L.P. |
13D/G
Dr. James I. Healy ("Healy")
|
4.2%
Reported 13D/G
· 11 Sep 2025
|
$29,155,258
1,947,579 shares
|
$0 | 11 Sep 2025 |
| Third Rock Ventures GP V, LP |
3/4/5
Director, 10%+ Owner
|
—
denominator unverified
|
$291,591,350
8,678,314 shares
|
-$34,391,226 | 30 Oct 2026 |
| Third Rock Ventures GP VI, L.P. |
3/4/5
Director, 10%+ Owner
|
—
denominator unverified
|
$291,591,350
8,678,314 shares
|
-$34,391,226 | 30 Oct 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$197,153,540.
Buys
$22,023,904
Insiders: 7
Sells
$219,177,444
Insiders: 10
Net
-$197,153,540
Shares: -4,428,500
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,031,174
Shares: 5,459,674
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 1,031,174 | 96,637 | $22,023,904 | $4,490,340 | +$17,533,565 |
| 3-6 | 0 | 191,571 | $0 | $8,060,387 | -$8,060,387 |
| 6-9 | 0 | 5,098,811 | $0 | $204,612,573 | -$204,612,573 |
| 9-12 | 0 | 72,655 | $0 | $2,014,145 | -$2,014,145 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to Rapport Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
Third Rock Ventures V, L.P.
Net 12M change
-$197.15M
Full value: -$197,153,541 · USD · 12-month changeLatest report
30 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | Director, 10%+ Owner | $291,591,350 | -$34,391,226 | -11% | Median | 30 Oct 2026 |
| Third Rock Ventures GP V, LP | Director, 10%+ Owner | $291,591,350 | -$34,391,226 | -11% | Median | 30 Oct 2026 |
| TRV GP V, LLC | Director, 10%+ Owner | $291,591,350 | -$34,391,226 | -11% | Median | 30 Oct 2026 |
| Third Rock Ventures VI, L.P. | Director, 10%+ Owner | $291,591,350 | -$34,391,226 | -11% | Median | 30 Oct 2026 |
| Third Rock Ventures GP VI, L.P. | Director, 10%+ Owner | $291,591,350 | -$34,391,226 | -11% | Median | 30 Oct 2026 |
| TRV GP VI, LLC | Director, 10%+ Owner | $291,591,350 | -$34,391,226 | -11% | Median | 30 Oct 2026 |
| James Healy | Director | $61,671,673 | +$20,359,080 | +49% | Mixed | 28 Oct 2026 |
| ARCH Venture Partners XII, LLC | 10%+ Owner | $37,212,805 | Mixed | 10 Jun 2024 | ||
| Steven M. Paul | Director | $18,159,983 | +$974,278 | +5.7% | Mixed | 22 Oct 2026 |
| Abraham Ceesay | Chief Executive Officer, Director | $16,566,418 | -$5,992,812 | -27% | Mixed | 21 Oct 2026 |
| Krishnaswamy Yeleswaram | Chief Development Officer | $10,000,243 | -$4,457,670 | -31% | Filing P/S | 24 Aug 2026 |
| Cheryl Gault | Chief Operating Officer | $4,722,881 | -$1,238,263 | -21% | Filing P/S | 30 Sep 2026 |
| Bradley S. Galer | Chief Medical Officer | $1,970,311 | Mixed | 06 Jun 2024 | ||
| David Bredt | Chief Scientific Officer | $707,535 | -$1,141,345 | -62% | Mixed | 17 Feb 2026 |
| Reid M. Huber | Director | $499,373 | Filing P/S | 10 Jun 2026 | ||
| Troy A. Ignelzi | Chief Financial Officer | $404,550 | +$143,550 | +55% | Filing P/S | 21 Oct 2026 |
| Wendy B. Young | Director | $350,696 | +$99,992 | +40% | Filing P/S | 22 Oct 2026 |
| John Maraganore | Director | $253,318 | +$248,891 | +5622% | Filing P/S | 22 Oct 2026 |
| Paul M. Silva | Director | $99,636 | +$99,636 | +100% | Filing P/S | 22 Oct 2026 |
| Ramiro Sanchez | Director | $98,477 | +$98,478 | +100% | Filing P/S | 23 Oct 2026 |
Recent insider transactions for Rapport Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 122.8% | 1,190,476 | 2,159,694 | 30 Oct 2026 | By Third Rock Ventures VI, L.P. | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 122.8% | 1,190,476 | 2,159,694 | 30 Oct 2026 | By Third Rock Ventures VI, L.P. | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 122.8% | 1,190,476 | 2,159,694 | 30 Oct 2026 | By Third Rock Ventures VI, L.P. | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 122.8% | 1,190,476 | 2,159,694 | 30 Oct 2026 | By Third Rock Ventures VI, L.P. | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 122.8% | 1,190,476 | 2,159,694 | 30 Oct 2026 | By Third Rock Ventures VI, L.P. | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 122.8% | 1,190,476 | 2,159,694 | 30 Oct 2026 | By Third Rock Ventures VI, L.P. | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 3.79% | 238,095 | 6,518,620 | 30 Oct 2026 | Direct | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 3.79% | 238,095 | 6,518,620 | 30 Oct 2026 | Direct | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 3.79% | 238,095 | 6,518,620 | 30 Oct 2026 | Direct | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 3.79% | 238,095 | 6,518,620 | 30 Oct 2026 | Direct | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 3.79% | 238,095 | 6,518,620 | 30 Oct 2026 | Direct | ||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Award | 3.79% | 238,095 | 6,518,620 | 30 Oct 2026 | Direct | ||
| James Healy | RAPP | Common Stock | Purchase | 37.8% | $145,593 | $21.00 | 6,933 | 25,267 | 28 Oct 2026 | By SummitTX Pinnacle Master, L.P. - Healthcare 3 |
| James Healy | RAPP | Common Stock | Purchase | 33.8% | $79,212 | $21.00 | 3,772 | 14,924 | 28 Oct 2026 | By SummitTX Master, SPC - SummitTX Alpha SP - Healthcare 3 |
| James Healy | RAPP | Common Stock | Purchase | 55.2% | $134,295 | $21.00 | 6,395 | 17,990 | 28 Oct 2026 | By SummitTX Master, SPC -SummitTX Apex SP - Healthcare 3 |
| James Healy | RAPP | Common Stock | Purchase | 51.1% | $19,999,980 | $21.00 | 952,380 | 2,815,707 | 28 Oct 2026 | By Sofinnova Venture Partners XI, L.P. |
| Ramiro Sanchez | RAPP | Common Stock | Purchase | $98,478 | $27.35 | 3,600 | 3,600 | 23 Oct 2026 | Direct | |
| Paul M. Silva | RAPP | Common Stock | Purchase | $99,636 | $27.08 | 3,680 | 3,680 | 22 Oct 2026 | By Paul M Silva 2016 Declaration of Trust U/A DTD 12/19/2016 | |
| Wendy B. Young | RAPP | Common Stock | Purchase | 39.9% | $99,992 | $26.39 | 3,789 | 13,289 | 22 Oct 2026 | Direct |
| Steven M. Paul | RAPP | Common Stock | Purchase | 85.7% | $974,278 | $27.28 | 35,714 | 77,380 | 22 Oct 2026 | By Paul Capital Strategy III Fund LLC |
| John Maraganore | RAPP | Common Stock | Purchase | $248,891 | $26.45 | 9,411 | 9,411 | 22 Oct 2026 | By John M. Maraganore Revocable Trust | |
| Abraham Ceesay | RAPP | Common Stock | Sale | -0.49% | -$64,448 | $29.16 | -2,210 | 450,035 | 21 Oct 2026 | Direct |
| Troy A. Ignelzi | RAPP | Common Stock | Purchase | 55% | $143,550 | $26.10 | 5,500 | 15,500 | 21 Oct 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -0.25% | -$35,167 | $30.66 | -1,147 | 452,245 | 07 Oct 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -0.74% | -$108,106 | $32.03 | -3,375 | 453,392 | 06 Oct 2026 | Direct |
| Cheryl Gault | RAPP | Common Stock | Sale | -6.67% | -$331,856 | $33.19 | -10,000 | 139,914 | 30 Sep 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -0.48% | -$86,565 | $39.17 | -2,210 | 456,767 | 23 Sep 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -1.76% | -$374,498 | $45.61 | -8,210 | 458,977 | 08 Sep 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -3.89% | -$937,957 | $49.57 | -18,921 | 467,187 | 25 Aug 2026 | Direct |
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -15.9% | -$1,873,605 | $50.64 | -37,000 | 195,862 | 25 Aug 2026 | Direct |
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -5.35% | -$657,978 | $50.00 | -13,160 | 232,862 | 24 Aug 2026 | Direct |
| Krishnaswamy Yeleswaram | RAPP | Common Stock | Sale | -0.16% | -$20,160 | $49.90 | -404 | 246,022 | 19 Aug 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -5.62% | -$1,390,405 | $48.01 | -28,958 | 486,108 | 11 Aug 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -4.19% | -$1,042,772 | $46.26 | -22,541 | 515,066 | 10 Aug 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -0.41% | -$93,061 | $42.11 | -2,210 | 537,607 | 27 Jul 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -1.5% | -$328,437 | $40.00 | -8,210 | 539,817 | 14 Jul 2026 | Direct |
| Cheryl Gault | RAPP | Common Stock | Sale | -6.25% | -$415,798 | $41.58 | -10,000 | 149,914 | 30 Jun 2026 | Direct |
| Abraham Ceesay | RAPP | Common Stock | Sale | -1.48% | -$327,398 | $39.83 | -8,220 | 548,027 | 29 Jun 2026 | Direct |
| John Maraganore | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Robert J. Perez | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Steven M. Paul | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Paul M. Silva | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| James Healy | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Reid M. Huber | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Wendy B. Young | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Ramiro Sanchez | RAPP | Stock Option (Right to Buy) | Award | 15,200 | 15,200 | 10 Jun 2026 | Direct | |||
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | -$743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | -$743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | -$743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
| Third Rock Ventures V, L.P. | RAPP | Common Stock | Sale | -0.29% | -$743,753 | $40.05 | -18,572 | 6,280,525 | 26 May 2026 | Direct |
* marks a reported price that did not pass the local price check.